UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sickle cell disease in Germany: Results from a national registry

Pediatric blood & cancer, 2020-04, Vol.67 (4), p.e28130-n/a

2020

Volltextzugriff (PDF)

Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study

BMC cancer, 2010-11, Vol.10 (1), p.607-607, Article 607

2010

Volltextzugriff (PDF)

Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma

BMC cancer, 2010-03, Vol.10 (1), p.96-96, Article 96

2010

Volltextzugriff (PDF)

Efficacy, predictors of therapy response, and safety of sertraline in routine clinical practice: Prospective, open-label, non-interventional postmarketing surveillance study in 1878 patients

Journal of affective disorders, 2005-08, Vol.87 (2), p.271-279

2005

Volltextzugriff (PDF)

An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinical benefit - PANUSCO

BMC cancer, 2009-11, Vol.9 (1), p.412-412

2009

Volltextzugriff (PDF)

Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial

BMC cancer, 2015-05, Vol.15 (1), p.392-392, Article 392

2015

Volltextzugriff (PDF)

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

European journal of cancer (1990), 2015-03, Vol.51 (5), p.569-576

2015

Volltextzugriff (PDF)

Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study

Neuro-oncology (Charlottesville, Va.), 2018-05, Vol.20 (6), p.826-837

2018

Volltextzugriff (PDF)

Responsiveness of the PHQ-9 to Psychopharmacological Depression Treatment

Psychosomatics (Washington, D.C.), 2006, Vol.47 (1), p.62-67

2006

Volltextzugriff (PDF)

Phase II trial of ipilimumab in patients with advanced melanoma and spontaneous preexisting immune response to NY-ESO-1 (CTLA-4 NY-ESO-1)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e20061-e20061

2015

Volltextzugriff (PDF)

A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2001-2001

2018

Volltextzugriff (PDF)

Phase 1/2 intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.10535-10535

2018

Volltextzugriff (PDF)

Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N 2 M 2

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.12090-12090

2018

Volltextzugriff (PDF)

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

Clinical epigenetics, 2019-12, Vol.11 (1), p.188-188, Article 188

2019

Volltextzugriff (PDF)

Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas

Journal of biopharmaceutical statistics, 2015-11, Vol.25 (6), p.1285-1311

2015

Volltextzugriff (PDF)

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]

BMC cancer, 2008-11, Vol.8 (1), p.349-349, Article 349

2008

Volltextzugriff (PDF)

N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma

Neuro-oncology (Charlottesville, Va.), 2019-01, Vol.21 (1), p.95-105

2019

Volltextzugriff (PDF)

ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi8-vi9

2018

Volltextzugriff (PDF)

A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS2082-TPS2082

2016

Volltextzugriff (PDF)

Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N²M²)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS2084-TPS2084

2016

Volltextzugriff (PDF)

Lapatinib versus lapatinib plus capecitabine as second-line treatment in HER-2-overexpressing metastatic gastro-esophageal cancer (GC): A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.112-112

2015

Volltextzugriff (PDF)

Sample sizes for time-to-event endpoints: Should you insure against chance variations in accrual?

Contemporary clinical trials, 2012-03, Vol.33 (2), p.456-458

2012

Volltextzugriff (PDF)

An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2ndor higher line chemotherapy regarding clinical benefit - PANUSCO

BMC cancer, 2009-11, Vol.9 (1), Article 412

2009

Volltextzugriff (PDF)

An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2.sup.nd .sup.or higher line chemotherapy regarding clinical benefit - PANUSCO

BMC cancer, 2009-11, Vol.9, p.412

2009

Volltextzugriff (PDF)

On the Use of Abstract Models for RDF/S Provenance

Linked Data Management, 2014, p.419-440

2014

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(24)
Buchkapitel
(1)

Sprache

Englisch
(25)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Sickle cell disease in Germany: Results from a national registry

Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study

Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma

Efficacy, predictors of therapy response, and safety of sertraline in routine clinical practice: Prospective, open-label, non-interventional postmarketing surveillance study in 1878 patients

An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinical benefit - PANUSCO

Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study

Responsiveness of the PHQ-9 to Psychopharmacological Depression Treatment

Phase II trial of ipilimumab in patients with advanced melanoma and spontaneous preexisting immune response to NY-ESO-1 (CTLA-4 NY-ESO-1)

A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16)

Phase 1/2 intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N 2 M 2

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]

N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma

ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS

A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16)

Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N²M²)

Lapatinib versus lapatinib plus capecitabine as second-line treatment in HER-2-overexpressing metastatic gastro-esophageal cancer (GC): A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Sample sizes for time-to-event endpoints: Should you insure against chance variations in accrual?

An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2ndor higher line chemotherapy regarding clinical benefit - PANUSCO

An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2.sup.nd .sup.or higher line chemotherapy regarding clinical benefit - PANUSCO

On the Use of Abstract Models for RDF/S Provenance

Suchergebnisse filtern